Keywords: trimeris/roche, fuzeon, sales, leap, first, quarter, firm

Trimeris/Roche's Fuzeon sales leap 72% in first quarter of 2005

Article | 25 April 2005

Print This

US firm Trimeris, the developer of the HIV/AIDS drug Fuzeon (enfuvirtide) which is sold by Switzerland's Roche, says that ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in